3, 4 Methylenedioxymethamphetamine (MDMA), Ecstasy, a synthetic analogue of amphetamine and mescaline, is a -commonly used recreational drug of abuse and has recently been the focus of tremendous controversy. It has received wide publicity in the popular press and medical journals (Lancet, 1996) and a wide range of psychopathology ranging from panic attacks, depression to psychotic depression has been reported (McGuire et al.,1994) . Concerns about the. abuse potential of any centrally active or mood altering drugs are not new (Sheppard, 1970) . There have been reports of abuse of amitriptyline in combination with methadone (Cohen et al ,1978 , Cantor,1979 and recently dothiepin misuse has also been reported' (Dorman et al.,1995) and the patients who misuse dothiepin report euphoria and sedation with complex visual and auditory hallucinations. Experiences are pleasant and seem to occur in clouded consciousness.
Reports from some of our patients suggest that selective serotonin re-uptake inhibitor antidepressants combined with MDMA is becoming popular with people who go to metropolitan clubs and-raves. We are told good quality MDMA is becoming harder to find and so users are resorting to drug combinations to enhance its effects, such as MDMA combined with ketamine, an anaesthetic agent, and with fluoxetine (Singh, 1995) .
Here we report two cases of misuse of SSRI antidepressants, fluoxetine and sertraline in combination with MDMA. Case 1. Mr. A, a 45 year old ex-dancer suffering from HIV infection and no past psychiatric illness was receiving treatment for a mi'd depressive illness and was on fluoxetine 20 mg daily. Occasionally he used to go to discos and he used to take MDMA. He noticed that the days he took Ecstasy, within an hour he felt' a rush and enough energy to dance for 2 to 3 hours'. He also felt that by combining fluoxetine this effect was prolonged by a further two hours and there was an absence of hangover effects and the comedown was easier'.
Case 2 : Mr. B, a 24 year old unemployed man suffering from HIV infection with no past history of psychiatric illness was prescribed sertraline 50 mg daily by a physician apparently for mild depressive illness. He had extensive experience with Ecstasy before using it in combination with sertraline. Typically he would ingest 50 mg of sertraline before taking Ecstasy and his subjective experience was almost identical to that of the first case. He also experienced initially a rush, prolonged effect, easier comdown following a high and it stopped comedown depression' and absence of hangover effects.
DISCUSSION
The cerebral cortex in many mammals is inervated by two morpholosically distinct classes of 5-HT axon terminals, fine and beaded one. These two types of axon have different regional and laminer distribution and are differentially sensitive to neurotoxic effects of certain amphetamine derivatives, which includes Ecstasy. Administration of Ecstasy to various animals has been shown to cause long term destruction of serotonergic axons and axon terminals in the brain (Green & Goodwin, 1995) . The fine axons are much more sensitive to neurotoxic effects than the beaded axons, and the loss of fine axons lasts for months, whereas the beaded axons remain uneffected following neurotoxic drug treatment (Mamounas et al., 1991 ). An individual using Ecstasy utilise doses approaching those shown to be neurotoxic in nonhuman primats and indeed a 26% decrease in 5-hydroxy indoleacetic acid in cerebral spinal fluid was found it Ecstasy users (Ricaurte et al., 1990) . Green & Goodwin (1995) stated that Ecstasy can cause neurotoxicity to those serotonergic systems of the brain in human being, however, this has been questioned (Saunders, 1996) . There is no doubt the misuse of Ecstasy produces neuropsychiatry complications (Macguire et al.,1994) In addition to effecting serotonergic system it has also been observed that Ecstasy reduces CSF, HVA (homovallenic acid) particularly in women (McCann et al.,1994) , a finding that is in keeping with the observation that at high doses, Ecstasy can damage dopaminergic as well as serotonergic neurons (Commins et al., 1987) and a recent crosssectional association study, suggested evidence for specefic serotonergic neurotoxicity of MDMA in humans, using serotonin transporters legend [ 123 l] IJ-CIT (SempleetaL, 1999) .
In the laboratory, SSRI block MDMA induced serotonin release and they also block MDMA neurotoxicity and it has also been reported that fluoxetine does not block MDMAs reinforcing subjective effect (McCann & Recaurte,1993 ).
The two cases described here also suggest that the selective serotonin reuptake inhibitors, fluoxetine and sertraline, at doses that interact with the serotonin uptake sites in human does not block the subjective effects of MDMA and also that Ecstasy osycho-active effects may be separate from its neurotoxic actions.
Cytochrome P450 2D6 has been implicated at the main enzyme involved in Ecstasy metabolism and the SSRIs, fluoxetine and sertraline are important inhibitors of this enzyme, suggesting that they could increase blood levels of Ecstasy and thus enhance its effect. What is not known is whether single doses of these SSRIs are sufficient to inhibit the enzyme. It would be interesting if someone could measure the rate of metabolism of Ecstasy, with and without single doses of SSRIs. Potential functional consequences of Ecstacy induced brain 5-HT neurotoxic lesions are not yet clear. If true, the health implications of this finding could be serious. Evidence is now mounting that Ecstasy can cause serotonergic, dopaminergic and other abnormality in the neurotransmitter system and the effect of such a loss of "serotonergic/dopaminergic reserve" in later life is difficult to predict but could be clinically significant and these neurotransmitter systems are thought to be involved in the aetiology of various common psychiatric illnesses such as depression and schizophrenia. Our patients subjective experience suggest that SSRIs may be useful in limiting the adverse effects of Ecstasy as it appears to be mitigating the neurotoxic effects of MDMA. Theoretically atypical neuroleptics which blocks 5-HT and
